The Liverpool Heart And bRain Project (L-HARP): Protocol for an Observational Cohort Study of Cardiovascular Risk and Outcomes Following Stroke
Stephanie L Harrison, Deirdre A Lane, Benjamin J R Buckley, Kausik Chatterjee, Muath Alobaida, Emily Shipley, Gregory Y H Lip, Stephanie L Harrison, Deirdre A Lane, Benjamin J R Buckley, Kausik Chatterjee, Muath Alobaida, Emily Shipley, Gregory Y H Lip
Abstract
Further research is needed to refine risk prediction models for adverse cardiovascular outcomes following stroke in contemporary clinical practice, such as incident atrial fibrillation (AF), recurrent stroke, and cognitive impairment and dementia. The aims of this study are to prospectively investigate cardiovascular outcomes and risk factors for incident cardiovascular disease in a post-stroke cohort, and to externally validate, refine and expand current risk prediction models for cardiovascular and cardiovascular-related outcomes. The study sample size was based on the development of post-stroke risk prediction models for AF and was calculated as 1222 participants. The study design is a multicentre, prospective, observational cohort study. Participants will be adult patients admitted for ischaemic stroke confirmed by stroke physician or transient ischaemic attack (TIA) confirmed by MRI. Routinely collected data will be used in addition to the completion of simple validated questionnaires by the participants. Follow-up will be undertaken 12-months from the date of admission to hospital, in addition to linkage to routinely collected follow-up hospitalisation and mortality data. The primary outcomes are cardiovascular outcomes (including incident AF, stroke, TIA and myocardial infarction) at 12-month follow-up, all-cause mortality and mortality from cardiovascular causes, and incident cognitive impairment and dementia. Secondary outcomes include changes in function, depression, anxiety, fatigue and quality of life. The study has received approval from the Health Research Authority Research Ethics Committee (21/WA/0209), and is registered on https://www.clinicaltrials.gov/ (Identifier NCT05132465). Recruitment for the study began in October 2021 with completion of recruitment at all participating centres anticipated by October 2022.
Keywords: cohort study; epidemiology; risk prediction; stroke.
Conflict of interest statement
SLH reports grants from Bristol Myers Squibb (BMS) during the conduct of the study. DAL reports grants from BMS and personal fees from Boehringer Ingelheim and BMS/Pfizer outside the submitted work; received investigator-initiated educational grants from BMS, has been a speaker for Bayer, Boehringer Ingelheim, and BMS/Pfizer, and has consulted for BMS and Boehringer Ingelheim. BJRB: received funding from BMS/Pfizer. KC, MA and ES report no conflicts of interest. GYHL reports being a consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo and speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. The authors report no other potential conflicts of interest for this work.
© 2022 Harrison et al.
Figures
References
- Goff DC Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American heart association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S49–S73. doi:10.1161/01.cir.0000437741.48606.98
- Usher-Smith JA, Silarova B, Schuit E, Moons KG, Griffin SJ. Impact of provision of cardiovascular disease risk estimates to healthcare professionals and patients: a systematic review. BMJ Open. 2015;5(10):e008717. doi:10.1136/bmjopen-2015-008717
- Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2015;14(4):377–387. doi:10.1016/S1474-4422(15)70027-X
- Georgiopoulos G, Ntaios G, Stamatelopoulos K, et al. Comparison of risk scores for the prediction of the overall cardiovascular risk in patients with ischemic stroke: the Athens stroke registry. J Stroke Cerebrovasc Dis. 2019;28(12):104415. doi:10.1016/j.jstrokecerebrovasdis.2019.104415
- Bohula EA, Bonaca MP, Braunwald E, et al. Atherothrombotic risk stratification and the efficacy and safety of vorapaxar in patients with stable ischemic heart disease and previous myocardial infarction. Circulation. 2016;134(4):304–313. doi:10.1161/CIRCULATIONAHA.115.019861
- Fahey M, Crayton E, Wolfe C, Douiri A. Clinical prediction models for mortality and functional outcome following ischemic stroke: a systematic review and meta-analysis. PLoS One. 2018;13(1):e0185402. doi:10.1371/journal.pone.0185402
- Lim JS, Oh MS, Lee JH, et al. Prediction of post-stroke dementia using NINDS-CSN 5-minute neuropsychology protocol in acute stroke. Int Psychogeriatr. 2017;29(5):777–784. doi:10.1017/S1041610216002520
- Li YG, Bisson A, Bodin A, et al. C2 HEST score and prediction of incident atrial fibrillation in poststroke patients: a French nationwide study. J Am Heart Assoc. 2019;8(13):e012546. doi:10.1161/JAHA.119.012546
- Riley RD, Ensor J, Snell KIE, et al. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020;368:m441. doi:10.1136/bmj.m441
- Van Calster B, McLernon DJ, van Smeden M, et al. Calibration: the Achilles heel of predictive analytics. BMC Med. 2019;17(1):230. doi:10.1186/s12916-019-1466-7
- Khurshid S, Kartoun U, Ashburner JM, et al. Performance of atrial fibrillation risk prediction models in over 4 million individuals. Circ Arrhythm Electrophysiol. 2021;14(1):e008997. doi:10.1161/CIRCEP.120.008997
Source: PubMed